Aquestive Therapeutics (AQST) Return on Sales (2017 - 2026)

Aquestive Therapeutics' Return on Sales history runs 10 years deep, the most recent figure standing at 0.01% for Q1 2026.

• On a quarterly basis, Return on Sales rose 2.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.1%, a 9.0% decrease from a year earlier, with the FY2025 full-year figure at 0.89%, down 89.0% from the prior year.
• Return on Sales fell to 0.01% in Q1 2026 per AQST's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2025 and bottomed at 0.03% in Q1 2025.
• The 5-year median for Return on Sales is 0.01% (2024), against an average of 0.01%.
• Across the five-year window, Return on Sales gained 4 bps in 2022 and decreased 2 bps in 2024, its largest moves.
• Year by year, Return on Sales stood at 0.01% in 2022, then jumped by 47 bps to 0.01% in 2023, then tumbled by 134 bps to 0.01% in 2024, then soared by 172 bps to 0.01% in 2025, then slumped by 154 bps to 0.01% in 2026.
• Per Business Quant, the three latest AQST Return on Sales figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).